Europe Biological Buffers Market
Taille du marché en milliards USD
TCAC :
% 
USD
246.70 Million
USD
510.55 Million
2024
2035
 Période de prévision |
2025 –2035 |
 Taille du marché (année de référence) |
USD 246.70 Million |
 Taille du marché (année de prévision) |
USD 510.55 Million |
 TCAC |
% |
| Principaux acteurs du marché |
|
Segmentation du marché européen des tampons biologiques, par type de tampon (tampons de marchandises et autres tampons salins), formulation (poudre et liquide), application (produits pharmaceutiques et biopharmaceutiques, culture cellulaire et biologie moléculaire, applications cliniques et diagnostiques, et applications chimiques et industrielles, autres), utilisateur final (sociétés pharmaceutiques et biopharmaceutiques, sociétés de biotechnologie, instituts de recherche et universitaires, laboratoires de diagnostic, organismes de recherche sous contrat (CRO) et CMO) - Tendances et prévisions du secteur jusqu'en 2035
Analyse et taille du marché des tampons biologiques
Le marché européen des tampons biologiques est axé sur la production, la distribution et la vente de tampons biologiques. Il s'agit de solutions contenant un acide faible et sa base conjuguée (ou une base faible et son acide conjugué) utilisées pour maintenir un pH stable en laboratoire et en milieu biomédical. Ce marché englobe une large gamme de tampons biologiques, notamment les tampons phosphate, les tampons Tris, les tampons HEPES et autres, destinés à diverses applications dans des domaines tels que la recherche en sciences de la vie, les biotechnologies, l'industrie pharmaceutique et le diagnostic, entre autres.
Taille du marché des tampons biologiques
Data Bridge Market Research analyse que le marché européen des tampons biologiques devrait atteindre 510,55 millions USD d'ici 2035, contre 246,70 millions USD en 2024, avec un TCAC substantiel de 6,9 % au cours de la période de prévision de 2025 à 2035. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie par des experts, une analyse des importations/exportations, une analyse des prix, une analyse de la consommation de production et une analyse PESTLE.
Tendances du marché des tampons biologiques
« Adoption croissante des technologies basées sur l'IA »
Le marché des tampons biologiques connaît une évolution significative vers des solutions basées sur l'IA. Alors que les laboratoires et les entreprises biopharmaceutiques privilégient la précision, l'efficacité et la conformité réglementaire, l'intelligence artificielle et l'apprentissage automatique sont intégrés aux processus de formulation et de contrôle qualité des tampons. Ces technologies permettent d'optimiser la stabilisation du pH, d'améliorer les prévisions de performance des tampons et de rationaliser les flux de production. De plus, le besoin croissant de surveillance en temps réel et d'ajustements automatisés dans des secteurs comme le développement de médicaments, la recherche clinique et les bioprocédés stimule la demande. Face au durcissement des normes réglementaires et à l'accélération de la transformation numérique, les solutions de tampons biologiques basées sur l'IA sont en passe de devenir la norme du secteur.
Portée du rapport et segmentation du marché des tampons biologiques
|
Attributs |
Informations clés sur le marché des tampons biologiques |
|
Segments couverts |
|
|
Pays couverts |
Allemagne, Royaume-Uni, France, Italie, Espagne, Russie, Pays-Bas, Suisse, Turquie, Autriche, Pologne, Irlande, Norvège, Reste de l'Europe, |
|
Principaux acteurs du marché |
F. Hoffmann-La Roche Ltd (Suisse), Bio-Rad Laboratories, Inc. (États-Unis), Thermo Fisher Scientific Inc. (États-Unis), Takara Bio Inc. (Japon) et Merck KGaA (Allemagne), entre autres |
|
Opportunités de marché |
|
|
Ensembles d'informations de données à valeur ajoutée |
Outre les informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie par des experts, une analyse d'import/export, une analyse des prix, une analyse de la consommation de production et une analyse PESTLE. |
Définition du marché des tampons biologiques
Les tampons biologiques sont des solutions contenant un acide faible et sa base conjuguée (ou une base faible et son acide conjugué) qui résistent aux variations de pH lors de l'ajout d'un acide ou d'une base. Ils sont essentiels dans les systèmes biologiques et les laboratoires pour maintenir un pH stable, car les enzymes et autres biomolécules sont très sensibles aux fluctuations de pH. Les tampons biologiques courants comprennent le phosphate, le Tris et l'HEPES, chacun ayant une plage de tampons spécifique adaptée à différentes applications.
Dynamique du marché européen des tampons biologiques
Cette section vise à comprendre les moteurs, les avantages, les opportunités, les contraintes et les défis du marché. Tous ces éléments sont détaillés ci-dessous :
Conducteurs
- Prévalence croissante des maladies chroniques
La prévalence croissante des maladies chroniques, telles que le diabète, le cancer et les maladies cardiovasculaires, est un moteur important du marché européen des tampons biologiques. Cette croissance nécessite des efforts accrus en recherche et développement pour comprendre les mécanismes des maladies, développer des outils de diagnostic et formuler des traitements efficaces. Les tampons biologiques jouent un rôle crucial dans ces efforts, car ils fournissent les environnements de pH stables indispensables à la réalisation d'expériences et de tests précis dans divers domaines, notamment la culture cellulaire, la découverte de médicaments et l'analyse des protéines.
Par exemple,
- En janvier 2024, selon un article publié dans le NCBI, les maladies chroniques telles que le diabète, les maladies cardiaques, les accidents vasculaires cérébraux et le cancer contribuent depuis longtemps et continuent de contribuer de manière significative aux taux mondiaux de morbidité et de mortalité. Non seulement ces maladies affectent des millions de vies, mais elles pèsent également lourdement sur les systèmes de santé du monde entier. L'impact financier de la prise en charge des maladies chroniques devrait augmenter considérablement, leur coût mondial étant estimé à 47 000 milliards de dollars d'ici 2030. Ce chiffre alarmant met en évidence le fardeau croissant des maladies chroniques, qui nécessitent des soins médicaux continus, des traitements de pointe et des ressources de santé importantes.
- En juillet 2024, selon les données publiées par l'OMS, on estimait que 39,9 millions [36,1–44,6 millions] de personnes vivaient avec le VIH à la fin de 2023, dont 1,4 million [1,1–1,7 million] d'enfants (0–14 ans) et 38,6 [34,9–43,1 millions] d'adultes (15 ans et plus). 1,3 million [1,0–1,7 million] de personnes ont contracté le VIH en 2023. 120 000 [83 000–170 000] enfants ont contracté le VIH en 2023. 1,2 million [950 000–1,5 million] d'adultes ont contracté le VIH en 2023.
La prévalence de ces maladies varie selon le lieu : environ 17 % des personnes âgées en milieu rural et 29 % en milieu urbain sont touchées par des maladies chroniques. Parmi ces affections, l'hypertension et le diabète sont particulièrement répandus, représentant ensemble environ 68 % de l'ensemble des maladies chroniques chez les personnes âgées. Cela souligne l'urgence d'interventions de santé ciblées et de stratégies de prise en charge pour faire face au fardeau croissant des maladies chroniques au sein de la population vieillissante de l'Inde.
Adoption accrue des techniques Western BLOT et Elisa
Les techniques de Western Blot et d'Elisa sont fondamentales pour la recherche et le diagnostic en sciences de la vie, permettant la détection et la quantification de protéines et d'autres biomolécules. Avec l'expansion des efforts de recherche, notamment dans des domaines comme la découverte de médicaments, le diagnostic des maladies et l'identification de biomarqueurs, la demande pour ces techniques augmente, ce qui accroît le besoin de tampons fiables et de haute qualité, essentiels à des performances d'analyse optimales.
Par exemple,
- En avril 2023, un article publié dans la Bibliothèque nationale de médecine souligne l'utilisation croissante de la méthode ELISA (dosage immuno-enzymatique) en raison de sa polyvalence, de sa sensibilité et de sa spécificité pour la détection et la quantification des substances biologiques. Cette adoption croissante est due à son applicabilité au diagnostic médical, à la sécurité alimentaire et à la recherche. La capacité de la méthode ELISA à détecter un large éventail d'antigènes et d'anticorps, associée aux progrès de l'automatisation et du multiplexage, en fait une méthode privilégiée en milieu clinique et en laboratoire. La simplicité, la reproductibilité et la rentabilité de ce test contribuent également à son utilisation croissante.
- In April 2021, according to the article published in IUBMB Journals, Western Blot (WB), also known as immunoblot, is a fundamental method frequently employed by biologists to study various aspects of protein biomolecules. Beyond research, it is widely utilized in disease diagnosis due to its ability to directly detect proteins, making it a highly effective diagnostic tool routinely used in clinical settings. Its versatility and reliability have led to its widespread adoption in biology labs, establishing it as one of the most essential techniques for both research and clinical applications
Opportunities
- Increase in Public-Private Funding in Biomedical Research
As more financial resources allocated to scientific research and development, companies have the potential to invest in innovative formulations and technologies that enhance blocking buffer performance. This funding supports the creation of customized solutions tailored to specific applications, improving specificity and reducing background noise in assays. Additionally, it fosters collaboration with research institutions, leading to breakthroughs in buffer technology. Increased investment facilitates the development of environmentally friendly and sustainable products, aligning with growing consumer demand for eco-conscious solutions. Overall, tapping into this funding trend propels advancements in the blocking buffer market and fosters a competitive edge in a rapidly evolving landscape.
For instance,
- In May 2021, according to the article published in NCBI, the upsurge in public-private funding for biomedical research, coupled with the increasing applications of western blotting techniques and rising product innovations, creates a favorable environment for growth. This trend acts as a significant opportunity for the blocking buffer market to expand and evolve
- In March 2023, according to the article published in NCBI, Target 2035, an international federation of biomedical scientists, is leveraging open principles to create pharmacological tools for every human protein, essential for studying health and disease. As pharmaceutical companies contribute knowledge and reagents, this initiative presents a valuable opportunity for the blocking buffer market to grow and innovate
The recent surge in public-private funding offers a substantial opportunity for the blocking buffer market. Increased financial support for scientific research allows companies to invest in innovative formulations that improve buffer performance. This funding encourages the development of customized solutions, enhances specificity, and promotes collaboration with research institutions, ultimately advancing eco-friendly products. This trend positions the blocking buffer market for significant growth.
-
Analytical Methods for Food Safety and Environmental Testing
Industries such as food safety and environmental testing increasingly rely on precise analytical methods, where high-quality blocking buffers play a critical role in minimizing background noise and enhancing assay sensitivity. As regulatory standards become more stringent, the demand for effective blocking solutions in these sectors is set to rise. By developing specialized buffers tailored to the unique requirements of food safety testing—such as allergen detection and pathogen identification—and environmental monitoring—such as pollutant analysis—manufacturers may tap into a growing market. This targeted approach not only addresses specific industry needs but also helps establish a competitive advantage. Companies that innovate and offer customizable solutions for these niche applications may position themselves for significant growth within the broader blocking buffer market.
For instance,
- In September 2021, according to the article published in Springer Nature, the use of Enzyme-Linked Immunosorbent Assay (ELISA) techniques in food analysis highlights a significant opportunity for the blocking buffer market. Their sensitivity and specificity allow for the detection of various components, including pesticides and toxins. This versatility creates a valuable opportunity for specialized blocking buffers tailored to food safety applications
- In May 2020, according to the article published in Science Direct, the prevalence of chemical contamination in food presents a significant opportunity for the blocking buffer market. The competitive enzyme-linked immunosorbent assay (Cp-ELISA) is widely used for detecting these contaminants due to its high throughput and low cost, highlighting the need for effective blocking buffers to enhance assay performance
- In February 2020, according to the article published in Springer Nature, The monitoring of pharmaceuticals in aquatic environments using enzyme-linked immunosorbent assay (ELISA) techniques creates a valuable opportunity for the blocking buffer market. As the demand for accurate detection of contaminants grows, effective blocking buffers become essential for improving assay sensitivity and reliability in environmental testing
The rising geriatric population is a key driver in the Europe biological buffers market, as older adults are more susceptible to various eye conditions that can lead to corneal damage and the need for transplants. Age-related eye diseases, such as Fuchs' endothelial dystrophy, bullous keratopathy, and other degenerative corneal disorders, become more prevalent with advancing age, significantly increasing the demand for Biological Bufferss. Also, older adults are more likely to experience complications from cataract surgery or develop chronic conditions like diabetes, which can further contribute to corneal deterioration. As the Europe population ages, the number of individuals requiring biological bufferss is expected to rise, particularly in regions with rapidly aging demographics. This trend is further fueled by increased awareness about the availability and success rates of Biological Bufferss, as well as advancements in surgical techniques that offer better outcomes and faster recovery times for older patients. As a result, the growing geriatric population is a major factor driving the expansion of the Europe biological buffers market, highlighting the need for accessible and effective treatment options for age-related corneal diseases.
Restraint/Challenge
- Alternative Technologies and Approaches for Inhibiting Biological Buffers
The biological buffer market faces substantial challenges due to the rise of alternative methodologies and advanced techniques, such as label-free detection and microfluidics, which allow for precise interactions without the need for traditional blocking buffers, thereby reducing background noise. Innovations in immunoassays, including multiplexing, improve specificity and further lessen dependence on conventional blocking strategies. Moreover, the application of nanotechnology for targeted binding complicates the traditional role of biological buffers. As these alternatives gain traction, offering cost-effective solutions, they may introduce background noise in sensitive assays, creating a dual challenge. As these methods become more widely accepted in research and clinical applications, the market is under pressure to innovate and adapt, potentially shifting demand and altering the competitive landscape.
For instance,
- In July 2021, according to the article published in Springer Nature Limited, Cell-free gene expression (CFE) offers an alternative to traditional cell-based methods for protein synthesis and labeling in structural biology and proteomics. This innovative approach enhances specificity and reduces non-specific interactions, presenting a challenge in the blocking buffer market as demand shifts towards more efficient methodologies
- In March 2024, according to the article published in MDPI, the synthesis of fully synthetic copolymers based on pHPMA or poly(2-oxazoline), designed to suppress non-specific interactions. These copolymers could serve as potential replacements for BSA or other proteins in diagnostic assays, presenting a significant challenge in the blocking buffer market
- In August 2023, according to the article published in MDPI, the enhanced immunoblotting process by simplifying gel preparation, optimizing the electrophoresis buffer, and substituting methanol with ethanol to improve safety. These modifications boost efficiency nearly four-fold, allowing even low-quality antibodies to be visualized effectively. This innovation presents a challenge in the blocking buffer market.
Biological Buffers Market Scope
The Europe biological buffers market is categorized into four notable segments based on buffers type, formulation, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Buffers Type
- Goods Buffers
- Tris Buffers
- Tris (Tris(Hydroxymethyl)Aminomethane)
- Tris NA
- Tris-HCL
- Hepes Buffers
- Hepes
- Hepes NA
- Mops Buffers
- Mops
- Mops NA
- Mes Buffers
- MES
- MES NA
- Bis-Tris Buffers
- BIS-TRIS
- Bis-TRIS HCL
- Others
- Tris Buffers
- Other Salt-Based Buffers
- Phosphate Buffers
- Phosphate Buffered Saline (PBS)
- Sodium Phosphate
- Potassium Phosphate
- Acetate Buffers
- Sodium Acetate
- Potassium Acetate
- Citrate Buffers
- Sodium Citrate
- Citric Acid
- Amino Acid Buffers
- Glycine Buffer
- Histidine Buffer
- Phosphate Buffers
Formulation
- Powder
- Liquid
Application
- Pharmaceutical & Biopharmaceuticals
- Drug Development
- Vaccine Formulation
- Biologics Manufacturing
- Cell Culture & Molecular Biology
- PCR & Electrophoresis
- Cell Culture Media Preparation
- DNA & RNA Isolation
- Protein Purification
- Clinical & Diagnostic Applications
- In-Vitro Diagnostics (IVD)
- Clinical Testing Kits
- Chemical & Industrial Applications
- Biotechnology Research
- Food & Beverage Processing
- Others
End User
- Pharmaceutical & Biopharmaceutical Companies
- Biotechnology Companies
- Research & Academic Institutes
- Diagnostic Laboratories
- Contract Research Organizations (CROS) & CMOS
Biological Buffers Market Regional Analysis
Biological buffers market is analyzed, and market size insights and trends are provided by based on buffer type, formulation, application, and end user.
The countries covered in this market report are Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Austria, Poland, Ireland, Norway, rest of Europe,
Germany is expected to dominate the market due to high R&D spending, key market player presence, advanced infrastructure, a strong healthcare system, and stringent regulations.
Le Royaume-Uni devrait être le pays qui connaît la croissance la plus rapide sur le marché en raison de l'augmentation de ses dépenses de santé, de l'expansion de son industrie pharmaceutique avec une infrastructure de santé en développement et d'une prévalence croissante.
La section pays du rapport présente également les facteurs d'impact sur les marchés individuels et les changements de réglementation qui influencent les tendances actuelles et futures du marché. Des données telles que l'analyse des chaînes de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces du porteur et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. De plus, la présence et la disponibilité des marques régionales et les difficultés auxquelles elles sont confrontées en raison de la forte ou de la faible concurrence des marques locales et nationales, de l'impact des tarifs douaniers nationaux et des routes commerciales sont prises en compte lors de l'analyse prévisionnelle des données nationales.
Part de marché des tampons biologiques en Europe
Le paysage concurrentiel du marché fournit des détails par concurrent. Il comprend la présentation de l'entreprise, ses données financières, son chiffre d'affaires, son potentiel de marché, ses investissements en recherche et développement, ses nouvelles initiatives commerciales, sa présence régionale, ses sites et installations de production, ses capacités de production, ses forces et faiblesses, le lancement de nouveaux produits, leur ampleur et leur portée, ainsi que la prédominance de ses applications. Les données ci-dessus ne concernent que les activités des entreprises par rapport à leur marché.
Les leaders du marché des tampons biologiques opérant sur le marché sont :
- F. Hoffmann-La Roche SA (Suisse)
- Bio-Rad Laboratories, Inc. (États-Unis)
- Thermo Fisher Scientific Inc. (États-Unis)
- Takara Bio Inc. (Japon), Merck KGaA (Allemagne),
- Avantor, Inc. (États-Unis)
- Advancion Corporation (États-Unis)
- Santa Cruz Biotechnology Inc. (États-Unis)
- MP Biomedicals (États-Unis)
- Promega Corporation (États-Unis)
- Beckman Coulter, Inc. (États-Unis)
- QIAGEN (Allemagne)
- Laboratoires HiMedia (Inde)
- Cayman Chemical (États-Unis)
- Biosynth (Suisse)
- SERVA Electrophoresis GmbH (Allemagne)
- FUJIFILM Wako Pure Chemical Corporation (Japon)
- Reagecon Diagnostics Ltd (Irlande)
- GoldBio (États-Unis)
- nacalai.com (Japon)
- HOPAX (Taïwan)
Dernières évolutions du marché des tampons biologiques
- En février 2024, Roche a conclu un accord de collaboration avec PathAI afin d'étendre les capacités de pathologie numérique pour les diagnostics compagnons. Cette collaboration permet à Roche de bénéficier de la technologie d'IA avancée de PathAI pour améliorer les diagnostics compagnons. Elle garantit des solutions exclusives et sur mesure et accélère le développement d'algorithmes, tout en permettant à Roche de poursuivre le développement de ses propres diagnostics.
- En juillet 2024, Roche a annoncé l'acquisition réussie de la technologie Point of Care de LumiraDx, suite à l'obtention des autorisations antitrust et réglementaires nécessaires. Cette intégration a enrichi le portefeuille de diagnostics de Roche grâce à une plateforme conviviale qui consolide divers tests d'immuno-analyse et de chimie clinique. Cette acquisition visait à améliorer l'accès aux tests diagnostiques, notamment en médecine générale et dans les régions mal desservies, conformément à l'engagement de Roche en faveur de solutions de santé décentralisées.
- En juillet 2023, Bio-Rad et QIAGEN ont annoncé un accord de règlement de brevets et de licences croisées mettant fin à des litiges en cours concernant des technologies spécifiques. Ce partenariat permet aux deux entreprises d'enrichir leurs portefeuilles de produits et d'accélérer l'innovation dans le secteur des sciences de la vie, bénéficiant ainsi à leurs clients en leur offrant un accès plus large à des technologies de pointe et à des solutions améliorées en recherche et en diagnostic.
- En mai 2023, Thermo Fisher et BRIN se sont associés pour améliorer les capacités de recherche en Indonésie, en se concentrant sur l'avancement de l'innovation scientifique et de la collaboration dans les sciences de la vie, la biotechnologie et les études environnementales pour les chercheurs locaux.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE BIOLOGICAL BUFFERS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 EUROPE BIOLOGICAL BUFFER MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN THE U.S.
5.2 REGULATORY SUBMISSIONS
5.3 INTERNATIONAL HARMONIZATION
5.4 EUROPE REGULATORY SCENARIO
5.5 REGULATORY SUBMISSIONS
5.6 INTERNATIONAL HARMONIZATION
5.7 JAPAN REGULATORY SCENARIO
5.8 REGULATORY SUBMISSIONS
5.9 INTERNATIONAL HARMONIZATION
5.1 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASES
6.1.2 INCREASED ADOPTION OF WESTERN BLOT AND ELISA TECHNIQUES
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN ASSAY DEVELOPMENT
6.1.4 ADVANCEMENTS IN PROTEOMICS AND GENOMICS
6.2 RESTRAINTS
6.2.1 LIMITED SHELF LIFE OF BLOCKING BUFFERS
6.2.2 POTENTIAL OF CONTAMINATION OR BATCH INCONSISTENCIES FOR BIOLOGICAL BUFFERS
6.3 OPPORTUNITY
6.3.1 INCREASE IN PUBLIC-PRIVATE FUNDING IN BIOMEDICAL RESEARCH
6.3.2 ANALYTICAL METHODS FOR FOOD SAFETY AND ENVIRONMENTAL TESTING.
6.3.3 DIAGNOSTIC AND CLINICAL APPLICATIONS USE BLOCKING BUFFERS.
6.4 CHALLENGES
6.4.1 ALTERNATIVE TECHNOLOGIES AND APPROACHES FOR INHIBITING BIOLOGICAL BUFFERS.
6.4.2 DISRUPTIONS IN THE SUPPLY CHAIN OF BIOLOGICAL BUFFERS.
7 EUROPE BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE
7.1 OVERVIEW
7.2 GOODS BUFFERS
7.2.1 TRIS BUFFERS
7.2.2 HEPES BUFFERS
7.2.3 MOPS BUFFERS
7.2.4 MES BUFFERS
7.2.5 BIS-TRIS BUFFERS
7.3 OTHER SALT-BASED BUFFERS
7.3.1 PHOSPHATE BUFFERS
7.3.2 ACETATE BUFFERS
7.3.3 CITRATE BUFFERS
7.3.4 AMINO ACID BUFFERS
8 EUROPE BIOLOGICAL BUFFERS MARKET, BY FORMULATION
8.1 OVERVIEW
8.2 POWDER
8.3 LIQUID
9 EUROPE BIOLOGICAL BUFFERS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 PHARMACEUTICAL & BIOPHARMACEUTICALS
9.3 CELL CULTURE & MOLECULAR BIOLOGY
9.4 CLINICAL & DIAGNOSTIC APPLICATIONS
9.5 CHEMICAL & INDUSTRIAL APPLICATIONS
9.6 OTHERS
10 EUROPE BIOLOGICAL BUFFERS MARKET, BY END USER
10.1 OVERVIEW
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
10.3 BIOTECHNOLOGY COMPANIES
10.4 RESEARCH & ACADEMIC INSTITUTES
10.5 DIAGNOSTIC LABORATORIES
10.6 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CMOS
11 EUROPE BIOLOGICAL BUFFERS MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 U.K
11.1.3 FRANCE
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 RUSSIA
11.1.7 SWITZERLAND
11.1.8 TURKEY
11.1.9 AUSTRIA
11.1.10 POLAND
11.1.11 IRELAND
11.1.12 NORWAY
11.1.13 REST OF EUROPE
12 EUROPE BIOLOGICAL BUFFERS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT
14 COMPANY PROFILES
14.1 F. HOFFMANN-LA ROCHE LTD
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT UPDATES
14.2 BIO-RAD LABORATORIES, INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 THERMO FISHER SCIENTIFIC, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT UPDATES
14.4 TAKARA BIO INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 MERCK KGAA, DARMSTADT, GERMANY
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 ADVANCION CORPORATION
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 AVANTOR, INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BECKMAN COULTER
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 BIOSYNTH
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 FUJIFILM WAKO PURE CHEMICAL CORPORATION
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 GOLDBIO
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 HOPAX
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 HIMEDIA LABORATORIES
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MP BIOMEDICALS.
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 NACALAI TESQUE, INC.
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 PROMEGA CORPORATION
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 QIAGEN
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 REAGECON DIAGNOSTICS LTD
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 SANTA CRUZ BIOTECHNOLOGY INC.
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 SERVA ELECTROPHORESIS GMBH
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 TEVA PHARMACEUTICALS USA, INC.
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 2 EUROPE GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 3 EUROPE GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 4 EUROPE TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 5 EUROPE HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND
TABLE 6 EUROPE MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 7 EUROPE MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 8 EUROPE BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 9 EUROPE OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 10 EUROPE OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 11 EUROPE PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 12 EUROPE ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 13 EUROPE CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 14 EUROPE AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 15 EUROPE BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 16 EUROPE POWDER IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 17 EUROPE LIQUID IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 18 EUROPE BIOLOGICAL BUFFERS MARKET, BY APPLICATION,2018-2035 (USD THOUSAND)
TABLE 19 EUROPE PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 20 EUROPE PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 21 EUROPE CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 22 EUROPE CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 23 EUROPE CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 24 EUROPE CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 25 EUROPE CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 26 EUROPE CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 27 EUROPE OTHERS IN BIOLOGICAL BUFFERS MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 28 EUROPE BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 29 EUROPE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES IN ORTHODONTIC SUPPLIES MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 30 EUROPE BIOTECHNOLOGY COMPANIES IN ORTHODONTIC SUPPLIES MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 31 EUROPE RESEARCH & ACADEMIC INSTITUTES IN ORTHODONTIC SUPPLIES MARKET, BY REGION, 2018-2035 (USD THOUSAND)
TABLE 32 EUROPE DIAGNOSTIC LABORATORIES IN ORTHODONTIC SUPPLIES MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 EUROPE CONTRACT RESEARCH ORGANIZATIONS (CROS) IN ORTHODONTIC SUPPLIES MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 34 EUROPE BIOLOGICAL BUFFERS MARKET, BY COUNTRY, 2018-2035 (USD THOUSAND)
TABLE 35 EUROPE BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 36 EUROPE GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 37 EUROPE TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 38 EUROPE HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 39 EUROPE MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 40 EUROPE MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 41 EUROPE BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 42 EUROPE OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 43 EUROPE PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 44 EUROPE ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 45 EUROPE CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 46 EUROPE AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 47 EUROPE BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 48 EUROPE BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 49 EUROPE PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 50 EUROPE CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 51 EUROPE CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 52 EUROPE CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 53 EUROPE BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 54 GERMANY BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 55 GERMANY GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 56 GERMANY TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 57 GERMANY HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 58 GERMANY MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 59 GERMANY MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 60 GERMANY BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 61 GERMANY OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 62 GERMANY PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 63 GERMANY ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 64 GERMANY CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 65 GERMANY AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 66 GERMANY BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 67 GERMANY BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 68 GERMANY PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 69 GERMANY CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 70 GERMANY CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 71 GERMANY CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 72 GERMANY BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 73 U.K. BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 74 U.K. GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 75 U.K. TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 76 U.K. HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 77 U.K. MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 78 U.K. MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 79 U.K. BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 80 U.K. OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 81 U.K. PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 82 U.K. ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 83 U.K. CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 84 U.K. AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 85 U.K. BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 86 U.K. BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 87 U.K. PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 88 U.K. CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 89 U.K. CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 90 U.K. CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 91 U.K. BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 92 FRANCE BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 93 FRANCE GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 94 FRANCE TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 95 FRANCE HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 96 FRANCE MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 97 FRANCE MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 98 FRANCE BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 99 FRANCE OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 100 FRANCE PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 101 FRANCE ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 102 FRANCE CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 103 FRANCE AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 104 FRANCE BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 105 FRANCE BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 106 FRANCE PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 107 FRANCE CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 108 FRANCE CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 109 FRANCE CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 110 FRANCE BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 111 ITALY BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 112 ITALY GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 113 ITALY TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 114 ITALY HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 115 ITALY MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 116 ITALY MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 117 ITALY BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 118 ITALY OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 119 ITALY PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 120 ITALY ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 121 ITALY CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 122 ITALY AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 123 ITALY BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 124 ITALY BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 125 ITALY PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 126 ITALY CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 127 ITALY CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 128 ITALY CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 129 ITALY BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 130 SPAIN BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 131 SPAIN GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 132 SPAIN TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 133 SPAIN HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 134 SPAIN MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 135 SPAIN MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 136 SPAIN BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 137 SPAIN OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 138 SPAIN PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 139 SPAIN ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 140 SPAIN CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 141 SPAIN AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 142 SPAIN BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 143 SPAIN BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 144 SPAIN PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 145 SPAIN CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 146 SPAIN CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 147 SPAIN CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 148 SPAIN BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 149 RUSSIA BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 150 RUSSIA GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 151 RUSSIA TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 152 RUSSIA HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 153 RUSSIA MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 154 RUSSIA MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 155 RUSSIA BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 156 RUSSIA OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 157 RUSSIA PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 158 RUSSIA ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 159 RUSSIA CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 160 RUSSIA AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 161 RUSSIA BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 162 RUSSIA BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 163 RUSSIA PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 164 RUSSIA CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 165 RUSSIA CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 166 RUSSIA CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 167 RUSSIA BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 168 NETHERLAND
TABLE 169 NETHERLANDS BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 170 NETHERLANDS GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 171 NETHERLANDS TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 172 NETHERLANDS HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 173 NETHERLANDS MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 174 NETHERLANDS MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 175 NETHERLANDS BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 176 NETHERLANDS OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 177 NETHERLANDS PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 178 NETHERLANDS ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 179 NETHERLANDS CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 180 NETHERLANDS AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 181 NETHERLANDS BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 182 NETHERLANDS BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 183 NETHERLANDS PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 184 NETHERLANDS CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 185 NETHERLANDS CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 186 NETHERLANDS CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 187 NETHERLANDS BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 188 SWITZERLAND BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 189 SWITZERLAND GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 190 SWITZERLAND TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 191 SWITZERLAND HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 192 SWITZERLAND MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 193 SWITZERLAND MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 194 SWITZERLAND BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 195 SWITZERLAND OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 196 SWITZERLAND PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 197 SWITZERLAND ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 198 SWITZERLAND CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 199 SWITZERLAND AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 200 SWITZERLAND BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 201 SWITZERLAND BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 202 SWITZERLAND PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 203 SWITZERLAND CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 204 SWITZERLAND CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 205 SWITZERLAND CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 206 SWITZERLAND BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 207 TURKEY BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 208 TURKEY GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 209 TURKEY TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 210 TURKEY HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 211 TURKEY MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 212 TURKEY MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 213 TURKEY BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 214 TURKEY OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 215 TURKEY PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 216 TURKEY ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 217 TURKEY CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 218 TURKEY AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 219 TURKEY BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 220 TURKEY BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 221 TURKEY PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 222 TURKEY CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 223 TURKEY CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 224 TURKEY CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 225 TURKEY BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 226 AUSTRIA BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 227 AUSTRIA GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 228 AUSTRIA TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 229 AUSTRIA HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 230 AUSTRIA MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 231 AUSTRIA MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 232 AUSTRIA BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 233 AUSTRIA OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 234 AUSTRIA PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 235 AUSTRIA ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 236 AUSTRIA CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 237 AUSTRIA AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 238 AUSTRIA BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 239 AUSTRIA BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 240 AUSTRIA PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 241 AUSTRIA CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 242 AUSTRIA CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 243 AUSTRIA CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 244 AUSTRIA BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 245 POLAND BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 246 POLAND GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 247 POLAND TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 248 POLAND HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 249 POLAND MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 250 POLAND MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 251 POLAND BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 252 POLAND OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 253 POLAND PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 254 POLAND ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 255 POLAND CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 256 POLAND AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 257 POLAND BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 258 POLAND BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 259 POLAND PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 260 POLAND CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 261 POLAND CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 262 POLAND CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 263 POLAND BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 264 IRELAND BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 265 IRELAND GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 266 IRELAND TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 267 IRELAND HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 268 IRELAND MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 269 IRELAND MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 270 IRELAND BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 271 IRELAND OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 272 IRELAND PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 273 IRELAND ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 274 IRELAND CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 275 IRELAND AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 276 IRELAND BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 277 IRELAND BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 278 IRELAND PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 279 IRELAND CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 280 IRELAND CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 281 IRELAND CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 282 IRELAND BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 283 NORWAY BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
TABLE 284 NORWAY GOODS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 285 NORWAY TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 286 NORWAY HEPES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 287 NORWAY MOPS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 288 NORWAY MES BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 289 NORWAY BIS-TRIS BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TREATMENT TYPE, 2018-2035 (USD THOUSAND)
TABLE 290 NORWAY OTHER SALT-BASED BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 291 NORWAY PHOSPHATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 292 NORWAY ACETATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 293 NORWAY CITRATE BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 294 NORWAY AMINO ACID BUFFERS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 295 NORWAY BIOLOGICAL BUFFERS MARKET, BY FORMULATION, 2018-2035 (USD THOUSAND)
TABLE 296 NORWAY BIOLOGICAL BUFFERS MARKET, BY APPLICATION, 2018-2035 (USD THOUSAND)
TABLE 297 NORWAY PHARMACEUTICAL & BIOPHARMACEUTICALS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 298 NORWAY CELL CULTURE & MOLECULAR BIOLOGY IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 299 NORWAY CLINICAL & DIAGNOSTIC APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 300 NORWAY CHEMICAL & INDUSTRIAL APPLICATIONS IN BIOLOGICAL BUFFERS MARKET, BY TYPE, 2018-2035 (USD THOUSAND)
TABLE 301 NORWAY BIOLOGICAL BUFFERS MARKET, BY END USER, 2018-2035 (USD THOUSAND)
TABLE 302 REST OF EUROPE BIOLOGICAL BUFFERS MARKET, BY BUFFERS TYPE, 2018-2035 (USD THOUSAND)
Liste des figures
FIGURE 1 EUROPE BIOLOGICAL BUFFERS MARKET: SEGMENTATION
FIGURE 2 EUROPE BIOLOGICAL BUFFERS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE BIOLOGICAL BUFFERS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE BIOLOGICAL BUFFERS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE BIOLOGICAL BUFFERS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE BIOLOGICAL BUFFERS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE BIOLOGICAL BUFFERS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE BIOLOGICAL BUFFERS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE BIOLOGICAL BUFFERS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE BIOLOGICAL BUFFERS MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE EUROPE BIOLOGICAL BUFFERS MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2035
FIGURE 12 GOODS BUFFERS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BIOLOGICAL BUFFERS MARKET IN THE FORECAST PERIOD OF 2025 & 2035
FIGURE 13 EUROPE BIOLOGICAL BUFFERS MARKET EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 DROC
FIGURE 16 EUROPE BIOLOGICAL BUFFERS MARKET: BY BUFFER TYPE, 2024
FIGURE 17 EUROPE BIOLOGICAL BUFFERS MARKET: BY BUFFER TYPE, 2025-2035 (USD THOUSAND)
FIGURE 18 EUROPE BIOLOGICAL BUFFERS MARKET: BY BUFFER TYPE, CAGR (2025-2035)
FIGURE 19 EUROPE BIOLOGICAL BUFFERS MARKET: BY BUFFER TYPE, LIFELINE CURVE
FIGURE 20 EUROPE BIOLOGICAL BUFFERS MARKET: BY FORMULATION, 2024
FIGURE 21 EUROPE BIOLOGICAL BUFFERS MARKET: BY FORMULATION, 2025-2035 (USD THOUSAND)
FIGURE 22 EUROPE BIOLOGICAL BUFFERS MARKET: BY FORMULATION, CAGR (2025-2035)
FIGURE 23 EUROPE BIOLOGICAL BUFFERS MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 24 EUROPE BIOLOGICAL BUFFERS MARKET: BY APPLICATION, 2024
FIGURE 25 EUROPE BIOLOGICAL BUFFERS MARKET: BY APPLICATION, 2025-2035 (USD THOUSAND)
FIGURE 26 EUROPE BIOLOGICAL BUFFERS MARKET: BY APPLICATION, CAGR (2025-2035)
FIGURE 27 EUROPE BIOLOGICAL BUFFERS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 28 EUROPE BIOLOGICAL BUFFERS MARKET: BY END USER, 2024
FIGURE 29 EUROPE BIOLOGICAL BUFFERS MARKET: BY END USER, 2025-2035 (USD THOUSAND)
FIGURE 30 EUROPE BIOLOGICAL BUFFERS MARKET: BY END USER, CAGR (2025-2035)
FIGURE 31 EUROPE BIOLOGICAL BUFFERS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 EUROPE BIOLOGICAL BUFFERS MARKET: SNAPSHOT (2024)
FIGURE 33 EUROPE BIOLOGICAL BUFFERS MARKET: COMPANY SHARE 2024 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
